Osteoporosis - secondary prevention including strontium ranelate: appeal against the clinical and cost effectiveness of technologies for the primary and secondary prevention of osteoporosis
The clinical effectiveness and cost effectiveness of technologies for the primary preventionof osteoporotic fragility fractures in postmenopausal women AND Alendronate, etidronate,risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention ofosteoporotic fragility fractures in postmenopausal women Appeal
An appeal hearing was held on 22 October. The Institute awaits the decision of the appeal panel.
This page was last updated: 30 March 2010